Poor Performance Status
9
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
SR-WBV Training for Frail Elderly in the Skilling up Stage
Innovative Training Program for Elderly in Need of Care
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
Nighttime Feeding and Morning Endurance Performance
Innovative Training Program for Elderly in Need of Care Individuals
Innovative Training Methods for Frail Elderly in the Training Gain Stage
Saving Brain in Uganda and Burkina Faso
Minocycline Treatment in Acute Hemorrhagic Stroke